Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA)

SUNPHARMA Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	-	92,857	46,237	45,083	62,730	56,766
Short-Term Investments	-	53,712	60,041	44,695	32,592	48,595
Trading Asset Securities	-	44,332	45,022	36,771	310	4,037
Cash & Short-Term Investments	190,901	190,901	151,300	126,548	95,632	109,398
Cash Growth	26.17%	26.17%	19.56%	32.33%	-12.58%	-2.17%
Accounts Receivable	-	112,602	114,568	105,035	90,979	94,212
Other Receivables	-	6,188	4,136	3,509	7,366	9,410
Receivables	-	119,440	119,117	110,243	98,905	105,106
Inventory	-	102,949	109,683	92,392	93,618	82,692
Prepaid Expenses	-	4,135	3,718	2,862	2,787	1,858
Other Current Assets	-	17,325	15,015	16,601	13,479	17,488
Total Current Assets	-	434,750	398,833	348,646	304,421	316,542
Property, Plant & Equipment	-	113,001	113,537	111,689	111,715	112,263
Long-Term Investments	-	64,412	54,517	49,592	64,824	52,458
Goodwill	-	85,990	83,580	65,913	62,876	64,815
Other Intangible Assets	-	86,663	93,268	61,918	56,607	63,595
Long-Term Accounts Receivable	-	-	108.3	193.7	305.5	434.1
Long-Term Deferred Tax Assets	-	41,037	35,189	28,496	35,564	31,753
Other Long-Term Assets	-	28,769	28,396	31,623	40,348	40,658
Total Assets	-	854,629	807,436	698,078	676,667	682,525
Accounts Payable	-	56,533	56,815	44,898	39,737	35,836
Accrued Expenses	-	16,889	15,127	14,833	11,972	10,237
Short-Term Debt	-	28,444	59,583	4,685	24,449	55,494
Current Portion of Long-Term Debt	-	-	2,396	2,323	4,239	6,439
Current Portion of Leases	-	1,257	1,281	1,078	1,017	927.2
Current Income Taxes Payable	-	4,117	3,087	1,756	1,791	2,020
Current Unearned Revenue	-	1,265	1,567	1,930	2,143	1,717
Other Current Liabilities	-	61,339	59,214	100,582	76,110	44,394
Total Current Liabilities	-	169,844	199,070	172,085	161,456	157,064
Long-Term Debt	-	13.3	-	2,299	6,547	17,776
Long-Term Leases	-	3,023	5,599	2,518	2,434	2,513
Long-Term Unearned Revenue	-	4,887	5,699	6,188	7,186	7,593
Long-Term Deferred Tax Liabilities	-	1,551	316.9	318.6	445.1	581.4
Other Long-Term Liabilities	-	253.7	334.6	575.4	914.6	2,800
Total Liabilities	-	183,569	214,281	187,417	181,869	191,278
Common Stock	-	2,399	2,399	2,399	2,399	2,399
Additional Paid-In Capital	-	11,874	11,874	11,874	11,874	11,874
Retained Earnings	-	537,452	472,009	412,363	401,887	389,052
Comprensive Income & Other	-	84,942	73,671	53,476	48,467	49,319
Total Common Equity	636,668	636,668	559,954	480,112	464,628	452,645
Minority Interest	-	34,392	33,201	30,549	30,171	38,602
Shareholders' Equity	671,060	671,060	593,155	510,661	494,798	491,247
Total Liabilities & Equity	-	854,629	807,436	698,078	676,667	682,525
Total Debt	32,737	32,737	68,859	12,903	38,686	83,149
Net Cash (Debt)	158,164	158,164	82,441	113,645	56,946	26,249
Net Cash Growth	91.85%	91.85%	-27.46%	99.57%	116.94%	292.75%
Net Cash Per Share	65.95	65.92	34.36	47.37	23.73	10.94
Filing Date Shares Outstanding	2,403	2,399	2,399	2,399	2,399	2,399
Total Common Shares Outstanding	2,403	2,399	2,399	2,399	2,399	2,399
Working Capital	-	264,906	199,763	176,562	142,965	159,477
Book Value Per Share	265.35	265.35	233.38	200.10	193.65	188.65
Tangible Book Value	464,015	464,015	383,105	352,282	345,145	324,235
Tangible Book Value Per Share	193.39	193.39	159.67	146.82	143.85	135.14
Land	-	8,173	6,676	6,448	4,426	4,251
Buildings	-	63,610	61,395	57,836	57,091	55,814
Machinery	-	146,265	139,645	132,031	124,281	117,355
Construction In Progress	-	11,077	9,634	7,975	9,365	6,589

Source: S&P Capital IQ. Standard template. Financial Sources.